safety of new biologic agents for inflammatory bowel disease in the liver

S Magrì, L Chessa, M Demurtas… - European Journal of …, 2021 - journals.lww.com
New biologic agents (vedolizumab, ustekinumab and tofacitinib) represent an effective
treatment for inflammatory bowel diseases and have been recently approved. However, with …
被引用次数：5 相关文章

safety of new biologic agents for inflammatory bowel disease in the liver.

S Magrì, L Chessa, M Demurtas, F Cabras… - European Journal of …, 2021 - europepmc.org
Review article: safety of new biologic agents for inflammatory bowel disease in the liver. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
[PDF] archive.org

[PDF][PDF] inflammatory bowel disease in the liver

S Magrìa, L Chessab, M Demurtasc… - European Journal of …, 2020 - scholar.archive.org
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are a
heterogeneous group of chronic immune disorders of unclear etiology. Over the past …

safety of new biologic agents for inflammatory bowel disease in the liver

S Magrì, L Chessa, M Demurtas… - European Journal of …, 2020 - ingentaconnect.com
New biologic agents (vedolizumab, ustekinumab and tofacitinib) represent an effective
treatment for inflammatory bowel diseases and have been recently approved. However, with …

safety of new biologic agents for inflammatory bowel disease in the liver

S Magrì, L Chessa, M Demurtas… - European journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
New biologic agents (vedolizumab, ustekinumab and tofacitinib) represent an effective
treatment for inflammatory bowel diseases and have been recently approved. However, with …
[PDF] unica.it

[PDF][PDF] inflammatory bowel disease in the liver

S Magrìa, L Chessab, M Demurtasc… - European Journal of …, 2020 - iris.unica.it
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are a
heterogeneous group of chronic immune disorders of unclear etiology. Over the past …

safety of new biologic agents for inflammatory bowel disease in the liver

S Magrì, L Chessa, M Demurtas, F Cabras… - EUROPEAN JOURNAL …, 2021 - iris.unica.it
New biologic agents (vedolizumab, ustekinumab and tofacitinib) represent an effective
treatment for inflammatory bowel diseases and have been recently approved. However, with …